drugset / Trial / NCT01551225

Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder

NCT01551225

Phase 4 Completed 32 enrolled Maastricht University Medical Center
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will be executed according to a randomized double-blind placebo-controlled trial with two parallel groups, treated over the period of 6 months with escitalopram or placebo. Hypotheses: Escitalopram is more effective than placebo in the control of gastrointestinal symptoms, in irritable bowel syndrome (IBS) patients with panic disorder. Escitalopram is more effective than placebo in the control of psychiatric symptoms, in IBS patients with panic disorder.

Timeline

Start
2012-01
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Escitalopram Small molecule 10 mg